Evidence map›Paper›PMID 36105426›Full record

ArticleBJR open2022

Prospective multicentre analysis of the therapeutic approach and prognostic factors determining overall survival in elderly patients with non-small-cell lung carcinoma treated with curative intent.

Jon Cacicedo, Francisco Casquero, Arturo Navarro, Lorea Martinez-Indart, Olga Del Hoyo, Andere Frías, Roberto Ortiz de Zarate, David Büchser, Alfonso Gómez-Iturriaga, Iñigo San Miguel and 3 more

Open access · goldAbstract read
In one paragraph

Article in BJR open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Jon Cacicedo
Francisco CasqueroDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Arturo NavarroDepartment of Radiation Oncology, Instituto Catalan de Oncología, Avinguda de la Gran vía de l'Hospitalet, 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Lorea Martinez-IndartDepartment of Bioinformatics and Statistics, Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, Spain.
Olga Del HoyoDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Andere FríasDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Roberto Ortiz de ZarateDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
David BüchserDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Alfonso Gómez-Iturriaga
Iñigo San MiguelDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Fernan SuarezDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Adrian BarcenaDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Bizkaia Health Research Institute, Vizcaya, Spain.
Jose Luis López-GuerraDepartment of Radiation Oncology, Hospital Virgen Del Rocío, Av Manuel Siurot, Sevilla, Spain.
BioCruces Health research Institute · ESHospital de Cruces · ESHospital Universitario Virgen del Rocío · ESInstitut Català d'Oncologia · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To analyse patterns of treatment with curative intent commonly used in elderly patients with locally advanced non-small-cell lung carcinoma (NSCLC) and predictive factors of overall survival in routine clinical practice. Methods: This multicentre prospective study included consecutive patients aged ≥65 years old diagnosed with NSCLC between February 2014 and January 2018. Inclusion criteria: age ≥65 years, stage IIIA/IIIB NSCLC. Treatment decisions were taken by a multidisciplinary committee. Kaplan-Meier curves and log-rank test were used to identify which clinical/treatment-associated variables, or pre-treatment quality of life (QOL) considering EORTC QLQ-C30 (and LC13 module) were predictive of overall survival. Results: A total of 139 patients were recruited. Median follow-up was 9.9 months (1.18-57.36 months) with a median survival of 14 months (range 11-17 months). In the group>75-year-old patients, the committee recommended chemotherapy and sequential radiotherapy (55.6%) or radiotherapy alone (22.2%), rather than surgery (3.7%) or concomitant radiochemotherapy (16.5%). However, in 65- to 75-year-old patients, surgery and concomitant radiochemotherapy were recommended in half of cases (p=0.003). Regarding multivariate analysis, the risk of death was higher in patients with pre-existing heart disease (p=0.002), low score for physical functioning (p=0.0001), symptoms of dysphagia (p=0,01), chest pain (p=0.001), and those not undergoing surgical treatment (p=0.024). Conclusions: Patients >75 years received more conservative treatments. Surgery improved survival and should be carefully considered, regardless of patient age. Comorbidities and poor baseline QOL are predictive of shorter survival. Advances in knowledge: Measuring these parameters before treatment may help us to define a population of frail patients with a poorer prognosis to facilitate decision making in clinical practice.

Identifiers

PMID36105426
PMCPMC9459856
OpenAlexW4281563547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.